<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006106</url>
  </required_header>
  <id_info>
    <org_study_id>DFCI-98320</org_study_id>
    <secondary_id>CDR0000068117</secondary_id>
    <secondary_id>NCI-G00-1832</secondary_id>
    <nct_id>NCT00006106</nct_id>
  </id_info>
  <brief_title>ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while
      leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor
      cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may
      kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of ONYX-015 combined with cisplatin and
      fluorouracil in treating patients who have advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the feasibility and maximum tolerated dose (MTD) of intraarterial ONYX-015 in
      patients with advanced squamous cell cancer of the head and neck.

      II. Determine the feasibility and tolerability of intraarterial ONYX-015 at the MTD OR
      maximum theraputic dose, whichever is lower, in combination with intravenous cisplatin and
      fluorouracil in these patients.

      III. Determine the qualitative distribution of ONYX-015 within a limited tumor biopsy and a
      normal mucosal biopsy at different dose levels.

      IV. Determine the response of these patients to intraarterial ONYX-015. V. Determine the
      response of these patients to cisplatin and fluorouracil following intraarterial ONYX-015.

      PROTOCOL OUTLINE: This is a dose escalation study. Patients receive intraarterial infusions
      of ONYX-015. Treatment repeats once in 3-4 weeks in the absence of disease progression or
      unacceptable toxicity.

      Cohorts of 3-8 patients receive escalating doses of ONYX-015 until the maximum tolerated dose
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 patients
      experience dose limiting toxicity.

      Patients in cohorts 1-4 are followed for 5 days after infusion, weekly for 3 weeks, at week
      6, and monthly thereafter for 4 months.

      A fifth or final cohort of 10 patients will receive ONYX-015 at the MTD. If the MTD was not
      determined in cohorts 1-4, patients receive the highest dose administered to cohort 4.
      Beginning 1-2 days after ONYX-015 infusion, patients receive cisplatin IV over 30-60 minutes
      once and fluorouracil IV continuously over 4 days. Treatment repeats in 4 weeks in the
      absence of disease progression or unacceptable toxicity. Cisplatin and fluorouracil IV
      treatment continues every 3-4 weeks at the discretion of the treating oncologist.

      Patients in cohort 5 are followed for 5 days after initial infusion, weekly for 4 weeks, at
      week 8, and monthly thereafter for 4 months.

      PROJECTED ACCRUAL:

      A total of 23-28 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lip and Oral Cavity Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONYX-015</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Histologically confirmed squamous cell carcinoma of the head and neck (SCCHN) that is
             incurable by standard therapy

          -  Measurable or evaluable disease

          -  Multiple SCCHN primaries allowed

          -  Metastases allowed if tumor to be treated is confined to head and neck region

        --Prior/Concurrent Therapy--

          -  Biologic therapy: Recovered from prior biologic therapy

          -  Chemotherapy: At least 3 weeks since prior chemotherapy and recovered

          -  Endocrine therapy: Recovered from prior endocrine therapy

          -  Radiotherapy: At least 12 weeks since prior radiotherapy and recovered

          -  Surgery: Recovered from prior surgery

          -  Other: Recovered from any prior diagnostic or theraputic procedures

        --Patient Characteristics--

          -  Age: 18 to physiologic 79

          -  Performance status: ECOG 0-2

          -  Life expectancy: Over 3 months

          -  Hematopoietic: WBC greater than 3,000/mm3 OR Absolute neutrophil count greater than
             2,000/mm3; Platelet count greater than 100,000/mm3; Hemoglobin greater than 10 g/dL
             (transfusions allowed if not used solely to meet eligibility criteria)

          -  Hepatic: SGOT less than 2.5 times upper limit of normal (ULN); Alkaline phosphatase
             less than 3 times ULN; Bilirubin no greater than 1.5 times ULN

          -  Renal: Creatinine less than 1.6 mg/dL OR Creatinine clearance greater than 50 mL/min

          -  Cardiovascular: No active cardiovascular disease that would limit physical activity
             (i.e., ability to walk 50 feet without stopping)

          -  Pulmonary: No active pulmonary disease that would limit physical activity (i.e.,
             ability to walk 50 feet without stopping)

          -  Other: No other prior or concurrent malignancy within the past 3 years except limited
             basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
             Adequate and nutritionally balanced enteral intake of at least 1,800 kcal/day (enteral
             feeding tube dependent allowed); No intravenous alimentation as primary source of
             calories; No other serious illness or medical condition that would preclude study
             (i.e., active systemic lupus erythematosus, Crohn's disease or AIDS); No prior
             immunodeficiency (i.e., HIV infection, organ transplant, or chronic steroid use); Not
             pregnant or nursing; Negative pregnancy test; Fertile patients must use effective
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall R. Posner</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>cellular diagnosis, hypopharyngeal cancer</keyword>
  <keyword>cellular diagnosis, laryngeal cancer</keyword>
  <keyword>cellular diagnosis, lip and oral cavity cancer</keyword>
  <keyword>cellular diagnosis, nasopharyngeal cancer</keyword>
  <keyword>cellular diagnosis, oropharyngeal cancer</keyword>
  <keyword>cellular diagnosis, paranasal sinus and nasal cavity cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>hypopharyngeal squamous cell carcinoma</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>laryngeal squamous cell carcinoma</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>lip and oral cavity squamous cell carcinoma</keyword>
  <keyword>metastatic squamous neck cancer with occult primary</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>nasopharyngeal squamous cell carcinoma</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>oropharyngeal squamous cell carcinoma</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>paranasal sinus and nasal cavity squamous cell carcinoma</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage, hypopharyngeal cancer</keyword>
  <keyword>stage, laryngeal cancer</keyword>
  <keyword>stage, lip and oral cavity cancer</keyword>
  <keyword>stage, metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage, nasopharyngeal cancer</keyword>
  <keyword>stage, oropharyngeal cancer</keyword>
  <keyword>stage, paranasal sinus and nasal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ONYX015</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

